Results 31 to 40 of about 75,992 (272)

Nivolumab-Induced Ulcerative Keratitis-A Case Report [PDF]

, 2021
Purpose: To describe a case of nivolumab-induced ulcerative keratitis rapidly recovering on topical steroid treatment and to determine changes in cytokine levels in the tear fluid caused by nivolumab.
Nuijts, R., Losonczy, G., Gijs, M., Nuijts, R.M.M.A.   +3 more
core   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy

Journal for ImmunoTherapy of Cancer, 2019
Background Nivolumab is approved for mRCC patients who have received prior anti-angiogenic therapy but the duration of therapy required for sustained clinical benefit is unknown.
Moshe C. Ornstein, Laura S. Wood, Brian P. Hobbs, Kimberly D. Allman, Allison Martin, Michael Bevan, Timothy D. Gilligan, Jorge A. Garcia, Brian I. Rini   +8 more
doaj   +1 more source

Analyses of Nivolumab Exposure and Clinical Safety Between 3-mg/kg Dosing and 240-mg Flat Dosing in Asian Patients with Advanced Renal Cell Carcinoma in the Real-World Clinical Setting

Translational Oncology, 2020
We aimed to identify the clinical characteristics related to increased nivolumab exposure in Japanese patients with renal cell carcinoma (RCC) in real-world clinical setting.
Renpei Kato, Daiki Ikarashi, Tomohiko Matsuura, Shigekatsu Maekawa, Yoichiro Kato, Mitsugu Kanehira, Ryo Takata, Rie Tokuyama, Kanako Tamai, Naoto Harigai, Yukoh Nakazaki, Wataru Obara   +11 more
doaj   +1 more source

Nivolumab-associated acute glomerulonephritis: Case report and literature review

, 2016
<p><strong>Background:</strong> Immune checkpoint inhibitors are changing the landscape of oncologic treatment as they are significantly improving treatment of multiple malignancies.
Xu Zeng, M.D., Ph.D., Mario Biluci, M.D., Ph.D., Kyungsuk Jung, M.D., M.P.H. (5265064), Mario Biluci, M.D., Ph.D. (5265067), Xu Zeng, M.D., Ph.D. (5265070), Kyungsuk Jung, M.D., M.P.H.   +5 more
core   +1 more source

Nivolumab-induced sensory ganglionopathy

, 2023
Introduction Nivolumab is s a human monoclonal antibody. Due to its widespread use in many cancers, including Merkel cell carcinoma, adverse reactions associated with nivolumab, such as neuropathies, endocrinopathies, gastrointestinal problems, and skin ...
Coşkun, Özlem, Coşkun, Uğur, Selim Yalcin, Yalcin, Selim, Ugur Coskun, Yekta C. Sahin, Hasan Sahin, Şahin, Hasan, Ozlem Coskun, Şahin, Yekta C.   +9 more
core   +1 more source

Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047

Journal for ImmunoTherapy of Cancer
Background Treatment-free survival (TFS; time spent free of systemic anticancer therapy) is increasingly used to support traditional endpoints. TFS was previously evaluated in patients with advanced melanoma treated with nivolumab plus ipilimumab.
Dirk Schadendorf, Evan J Lipson, Christopher D Lao, Hussein Tawbi, Paolo A Ascierto, David F McDermott, Michael B Atkins, Georgina V Long, F Stephen Hodi, Andriy Moshyk, Meredith M Regan, Jennell Palaia, Abraham Selvan, Ravi Potluri, Sandip Ranjan, Sandeep Bilthare   +15 more
doaj   +1 more source

High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review

BMC Pulmonary Medicine, 2018
Background Nivolumab, an anti-programmed cell death-1 (PD-1) monoclonal antibody used as an immune checkpoint inhibitor, is commonly employed for its anti-tumor effects against various types of malignant tumors. However, its administration is complicated
N. Koyama, O. Iwase, E. Nakashima, K. Kishida, T. Kondo, Y. Watanabe, H. Takahashi, Y. Umebayashi, Y. Ogawa, H. Miura   +9 more
doaj   +1 more source

Real-world treatment sequencing and survival in previously treated advanced renal cell carcinoma patients receiving nivolumab monotherapy: a UK retrospective cohort study

BMC Cancer, 2022
Background The CheckMate 025 trial established nivolumab monotherapy as one of the standards of care in previously treated advanced or metastatic renal cell carcinoma (aRCC). However, supporting real-world data is lacking.
T. Waddell, K. Fife, R. Griffiths, A. Sharma, P. Dhokia, L. Groves, M. Hurst, C. Tsang, D. Sugrue, S. McKenna, J. Houghton, R. Carroll   +11 more
doaj   +1 more source

Pharmacokinetics and safety of subcutaneous nivolumab: results from the phase I/II CheckMate 8KX study

Journal for ImmunoTherapy of Cancer
Background CheckMate 8KX was a phase I/II study investigating the pharmacokinetics and safety of subcutaneous (SC) nivolumab±recombinant human hyaluronidase PH20 (rHuPH20).Methods Patients with advanced solid tumors who were immune-checkpoint inhibitor ...
Sara Lonardi, Christopher Jackson, R Donald Harvey, Armando Santoro, Iwona Lugowska, José Trigo, Anne O’Donnell, Richard North, Urvi Aras, Loes Maria Latten-Jansen, Linghui Li, Devanand Joseph, Bryan Bennett, Balmeet Gurm, Wee-Teck Ng, Aitana Calvo, Marcelo Garrido, Rastislav Bahleda, Matías Rodrigo Chacon, Heather E Vezina, Deepak Perumal   +20 more
doaj   +1 more source